Canbridge Pharmaceuticals (HKSE:01228) EV-to-EBIT : -0.39 (As of Jun. 04, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Canbridge Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Canbridge Pharmaceuticals's Enterprise Value is HK$158.8 Mil. Canbridge Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-404.6 Mil. Therefore, Canbridge Pharmaceuticals's EV-to-EBIT for today is -0.39.

The historical rank and industry rank for Canbridge Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

HKSE:01228' s EV-to-EBIT Range Over the Past 10 Years
Min: -3.46 Med: -0.38 Max: 0.5
Current: -0.39

During the past 5 years, the highest EV-to-EBIT of Canbridge Pharmaceuticals was 0.50. The lowest was -3.46. And the median was -0.38.

HKSE:01228's EV-to-EBIT is ranked worse than
100% of 425 companies
in the Biotechnology industry
Industry Median: 10.2 vs HKSE:01228: -0.39

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Canbridge Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was HK$438.9 Mil. Canbridge Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-404.6 Mil. Canbridge Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -92.18%.

Canbridge Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Canbridge Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Canbridge Pharmaceuticals EV-to-EBIT Chart

Canbridge Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

-2.31

-1.33

-1.08

Canbridge Pharmaceuticals Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial				-2.31	-	-1.33	-	-1.08

Competitive Comparison of Canbridge Pharmaceuticals's EV-to-EBIT

For the Biotechnology subindustry, Canbridge Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Canbridge Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Canbridge Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Canbridge Pharmaceuticals's EV-to-EBIT falls into.

Canbridge Pharmaceuticals EV-to-EBIT Calculation

Canbridge Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	158.811	/	-404.577
	=	-0.39

Canbridge Pharmaceuticals's current Enterprise Value is HK$158.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Canbridge Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-404.6 Mil.

Canbridge Pharmaceuticals (HKSE:01228) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Canbridge Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-404.577	/	438.90178
	=	-92.18 %

Canbridge Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was HK$438.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Canbridge Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-404.6 Mil.

Canbridge Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Canbridge Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Canbridge Pharmaceuticals (HKSE:01228) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Canbridge Pharmaceuticals Inc (HKSE:01228) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

MF1:Germany

Address

Building 21, No. 388 Xinping Street, Unit 18, 6th Floor, Suzhou Industrial Park,, Suzhou, CHN

Website

https://www.canbridgepharma.com

Canbridge Pharmaceuticals Inc is a global biopharmaceutical company. It is committed to the research, development, and commercialization of biotech therapies targeting rare diseases and rare oncology. The company's core product in the rare oncology area CAN008, is a glycosylated CD95-Fc fusion protein being developed for the treatment of glioblastoma multiforme (GBM). In the rare disease area, the company have seven biologics and small molecules products and product candidates for the treatment of Hunter Syndrome (MPS II) and other lysosomal storage disorders (LSDs), complement mediated disorders, hemophilia A, metabolic disorders, and rare cholestatic liver diseases including ALGS, PFIC and BA. Its pipeline consists of biologics, small molecules, and gene therapy solutions and 13 drugs.

Executives

Xue James Qun	2101 Beneficial owner
Athos Capital Limited	2102 Investment manager
Moskey Matthew Love	2201 Interest of corporation controlled by you
Schulte-hillen Friedrich Bela	2201 Interest of corporation controlled by you
Athos Asia Event Driven Master Fund	2101 Beneficial owner
Ctx Pharma Holdings Limited	2101 Beneficial owner
Kolchinsky Anna Inge Leonore Haas	2202 Interest of your spouse
Kolchinsky Peter	2305 Beneficiary of a trust
Ra Capital Management, L.p.	2102 Investment manager
Ra Capital Healthcare Fund Gp, Llc	2201 Interest of corporation controlled by you
Ra Capital Healthcare Fund, L.p.	2101 Beneficial owner
Wuxi Apptec Co., Ltd.
Qiming Corporate Gp Iv, Ltd.	2201 Interest of corporation controlled by you
Qiming Gp Iv, L.p.	2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p.	2101 Beneficial owner

Canbridge Pharmaceuticals (HKSE:01228) Headlines

No Headlines